Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amcenestrant - Sanofi

Drug Profile

Amcenestrant - Sanofi

Alternative Names: SAR 439859; SERD '859

Latest Information Update: 31 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Developer Alliance Foundation Trials; Breast International Group; European Organisation for Research and Treatment of Cancer; Sanofi
  • Class 2 ring heterocyclic compounds; Antineoplastics; Carboxylic acids; Chlorobenzenes; Ethers; Fluorinated hydrocarbons; Phenols; Pyrrolidines; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 19 Oct 2022 Adverse events and efficacy data from a phase II AMEERA-3 trial in Breast cancer presented at the 47th European Society for Medical Oncology Congress (ESMO 2022)
  • 23 Aug 2022 Discontinued - Phase-I for Breast cancer (In the elderly, In volunteers, In adults) in Germany (PO)
  • 23 Aug 2022 Discontinued - Phase-III for Breast cancer (Combination therapy, Early-stage disease, Adjuvant therapy) in Japan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top